{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:30Z","timestamp":1789013430350,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P32470-B"],"award-info":[{"award-number":["P32470-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaci.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T02:21:39Z","timestamp":1650939699000},"page":"1912-1918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?"],"prefix":"10.1016","volume":"149","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.04.020_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaip.2018.09.024","article-title":"The Data Registry of the European Competence Network on Mastocytosis (ECNM): set up, projects, and perspectives","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.020_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.020_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jaci.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.04.020_bib11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0889-8588(05)70294-X","article-title":"Kit signal transduction","volume":"14","author":"Taylor","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaci.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib16","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib18","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2022.04.020_bib19","first-page":"93","article-title":"Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT","volume":"4","author":"Valent","year":"2014","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.jaci.2022.04.020_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/09546634.2013.802274","article-title":"Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report","volume":"24","author":"Agarwala","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaci.2022.04.020_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.04.020_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2022.04.020_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.04.020_bib24","series-title":"Gleevec [package insert]","year":"2020"},{"key":"10.1016\/j.jaci.2022.04.020_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2022.04.020_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.04.020_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib28","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2022.04.020_bib29","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.04.020_bib30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib32","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1002\/ajh.26464","article-title":"Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.04.020_bib33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.04.020_bib34","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.04.020_bib35","series-title":"Avapritinib [package insert]","year":"2021"},{"key":"10.1016\/j.jaci.2022.04.020_bib36","doi-asserted-by":"crossref","first-page":"AB336","DOI":"10.1016\/j.jaci.2019.12.062","article-title":"PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent or smoldering systemic mastocytosis (SM) with symptoms inadequately controlled by standard therapy","volume":"145","author":"Akin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib37","doi-asserted-by":"crossref","first-page":"AB221","DOI":"10.1016\/j.jaci.2021.12.721","article-title":"A phase 2\/3 study of BLU-263 in patients with indolent systemic mastocytosis or monoclonal mast cell activation syndrome","volume":"149","author":"Castells","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib38","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2021-152770","article-title":"Preclinical data with KIT D816V inhibitor bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance","volume":"138","author":"Guarnieri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib39","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/ijms22052586","article-title":"Molecular background, clinical features and management of pediatric mastocytosis: status 2021","volume":"22","author":"Lange","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2022.04.020_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1744666X.2022.1993061","article-title":"Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis","volume":"18","author":"Fardos","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.020_bib41","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.020_bib42","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.jaip.2019.05.032","article-title":"Treatment of systemic mastocytosis in an infant with midostaurin","volume":"7","author":"Liu","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.020_bib43","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","article-title":"Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib","volume":"9","author":"Kudlaty","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922005590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922005590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:38:12Z","timestamp":1758793092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922005590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0091674922005590"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.04.020","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}